DTC Ads Should Be Better, Not Banned, In Wake Of Vioxx, Ex-FDAer Pitts Says
The response to the Vioxx withdrawal offers further evidence of the need for FDA and manufacturers to modify the "brief summary" requirement in direct-to-consumer ads, former Associate Commissioner for External Relations Peter Pitts said during a Nov. 10 Drug & Device Dialogue audio conference sponsored by F-D-C Reports and Polidais LLC
You may also be interested in...
The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers
Data from long-term Celebrex (celecoxib) post-marketing studies reassure FDA of the COX-2 inhibitor's safety, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said
The Vioxx withdrawal will prompt renewed debate over DTC advertising